The FTC sued Edwards in August 2025, citing competition concerns in the nascent TAVR-AR market amid a potential deal for ...

Edwards terminated the deal after the Federal Trade Commission moved to block the acquisition due to anticompetitive concerns ...

The success of TAVR has also sparked research into transcatheter solutions for other valve diseases, including mitral and ...

Regional variations in market growth reflect differences in healthcare infrastructure and adoption rates, with North America and Asia-Pacific leading the way. Companies operating in the market ...

After a six-month battle, Edwards Lifesciences has been forced to walk away from its nearly $1 billion takeover attempt of ...

St. Luke’s University Health Network has reached an important milestone in advanced heart care. Members of St. Luke’s ...

TAVR replaces the damaged aortic valve without the need for open-heart surgery. In this procedure, doctors insert a thin, ...

Advocate Sherman Hospital Care heart patient Diana Esposito, of Elgin, unfurled a giant “Bear Down” flag Sunday, Jan. 4, ...

Edwards Lifesciences (EW) stock is in focus as the company hikes 2026 outlook as it drops $945M JenaValve buyout deal after ...

The U.S. Federal Trade Commission (FTC) has secured a significant antitrust victory after a federal judge ruled to block ...

Edwards Lifesciences announced that it will not acquire JenaValve following a legal battle won by the U.S. Federal Trade ...

The U.S. Federal Trade Commission won a ruling on Friday blocking Edwards Lifesciences' acquisition of JenaValve Technology, ...